Lon­za un­veils two sep­a­rate vac­cine, ADC man­u­fac­tur­ing deals that could lead to 415 new Swiss jobs

Ahead of its Cap­i­tal Mar­kets Day on Tues­day, Lon­za an­nounced back-to-back part­ner­ship deals that cov­er two Swiss fa­cil­i­ty cus­tomiza­tions and the po­ten­tial cre­ation of around 415 new jobs once man­u­fac­tur­ing is at its peak.

On Mon­day, Lon­za and vac­cine biotech Vax­cyte said they are start­ing a new man­u­fac­tur­ing deal to sup­port the pro­duc­tion of Vax­cyte’s pneu­mo­coc­cal con­ju­gate vac­cines. In a Fri­day an­nounce­ment, the Swiss com­pa­ny al­so said it has ex­pand­ed its col­lab­o­ra­tion with an un­named “ma­jor bio­phar­ma­ceu­ti­cal part­ner” to meet its bio­con­ju­gate han­dling and fill­ing needs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.